News Tissue Repair Ltd

Equities

TRP

AU0000180887

Market Closed - Australian S.E. Other stock markets 11:02:08 03/05/2024 am IST			5-day change	1st Jan Change
0.245 ^AUD	0.00%		+6.52%	+11.36%

29/02	Tissue Repair Limited Announces Change of Company Secretary	CI
28/02	Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tissue Repair Limited Announces Change of Company Secretary	01/03	CI
Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	29/02	CI
Tissue Repair Secures Third US Patent for Glucoprime Compound	19/12	MT
17,604,240 Options of Tissue Repair Ltd are subject to a Lock-Up Agreement Ending on 18-NOV-2023.	18/11	CI
13,684,488 Ordinary Shares of Tissue Repair Ltd are subject to a Lock-Up Agreement Ending on 18-NOV-2023.	18/11	CI
Tissue Repair Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
Tissue Repair Limited Announces Company Secretary Changes	28/23/28	CI
Tissue Repair Secures US FDA Clearance for Phase Three Leg Ulcer Trial	29/23/29	MT
Tissue Repair Ltd Appoints Michael Silberberg as Director	02/23/02	CI
Tissue Repair Ltd Announces Board Resignations	26/23/26	CI
Tissue Repair Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	22/23/22	CI
Tissue Repair to Test TR-987 Drug in 2023	29/22/29	MT
Tissue Repair Ltd Announces Change of Company Secretary	28/22/28	CI
Tissue Repair Limited Announces That It Has Received Responses to the Matters Raised in the Type C Meeting That the Company Submitted to the FDA on June 29, 2022	28/22/28	CI
Tissue Repair Secures Second US Patent for Use of Active Ingredient in Skin Conditions	05/22/05	MT
Tissue Repair Limited to Enter a Phase 3 Program in Venous Leg Ulcers	05/22/05	CI
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)	23/22/23	AQ
3,770,440 Ordinary Shares of Tissue Repair Ltd are subject to a Lock-Up Agreement Ending on 30-APR-2022.	30/22/30	CI
Australian Shares Fall Amid Global Selloff as Russia Continues Assault on Ukraine	04/22/04	MT
Tissue Repair Secures US Patent Approval for Wound Drug; Shares Sink 8%	04/22/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Tissue Repair Ltd

Equities

TRP

AU0000180887

Summary

Filters